ClinicalTrials.gg
TerminatedNCT05307874EVICTION-2Updated Jul 30, 2026

Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of ICT01 and Proleukin Injectable Product in Solid Tumor, Adult, sponsored by ImCheck Therapeutics, an Ipsen company. Terminated at 5 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by ImCheck Therapeutics, an Ipsen company (part of Ipsen) · Phase 1/2, Interventional, and Treatment

Why this study was terminated
The study was terminated based on sponsor decision unrelated to safety or efficacy. The study met the key primary and secondary endpoints, however two patients were receiving treatment at the decision point, preventing protocol-defined completion.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
56
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a phase I/IIa, two-part, open-label study to characterize the safety, tolerability, pharmacodynamics, and antitumor activity of ICT01 in combination with LDSC IL-2 in patients with advanced-stage solid tumors.

Part 1 will be a dose escalation of IV ICT01 administered on the first day of every 21-day cycle (CnD1) to patients with advanced-stage solid tumors in combination with LDSC IL-2 (Proleukin®) administered daily on days 1-5 of cycles 1-3 (C1-3D1-5). Objectives of part 1 are to characterize the safety of the combination regimen and determine the RP2D for Part 2.

Part 2 will comprise a maximum of 2 indications and 2 combination dosing regimens of ICT01 +LDSC IL-2, which will be supported by statistical power calculations once the indications are selected. The final regimen will be ICT01 + LDSC IL-2 + Pembrolizumab on a Q3W cycle. The primary objective of Part 2 is to demonstrate the efficacy of the combination regimen based on RECIST1.1 in one or more solid tumor indications.

02

Conditions studied

  • Solid Tumor, Adult
03

In context

Lead sponsor

ImCheck Therapeutics, an Ipsen company is the lead sponsor of 2 studies on the registry; none are open to participants now.

First submitted before ImCheck Therapeutics became part of Ipsen.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. patients who have failed at least 2 or who failed first line therapy and are intolerant of or have a to the standard second line of therapy with or cytologically confirmed diagnosis of:

    1. colorectal cancer (CRC):
    2. metastatic ovarian cancer:
    3. metastatic castration-resistant prostate cancer (mCRPC)
    4. metastatic pancreatic ductal adenocarcinoma (PDAC)
    5. metastatic or unresectable refractory melanoma

      2) Availability of baseline tumor and willingness to undergo on-study tumor biopsies 3) (ECOG) performance status ≤ 1 4) > 3 months as assessed by the Investigator 5) At least 1 per RECIST1.1

Exclusion criteria

Exclusion Criteria:

  1. Any of γ9δ2 T cell origin
  2. Any systemic anti-tumor-directed drug therapy within 28 days or 5 times the elimination half-life (whichever is shorter) before study treatment
  3. Treatment with drugs within 28 days before study treatment
  4. Systemic at a daily dose of > 10 mg of prednisone, > 2 mg of dexamethasone or equivalent, for the last 28 days and ongoing
  5. Patients with rapidly progressing disease defined as advanced/, symptomatic, visceral spread, with a risk of life-threatening complications in the short term (e.g., during Screening Period/ treatment ) that includes patients with massive uncontrolled effusions pleural, pericardial, peritoneal, pulmonary lymphangitis, and over 50% liver involvement
  6. Ongoing immune-related adverse events (irAEs) ≥grade 2 not resolved from previous therapies except vitiligo, stable neuropathy up to grade 2, hair loss, and stable endocrinopathies with substitutive hormone therapy.
  7. Ongoing systemic disease requiring systemic therapy
  8. Primary or secondary immune deficiency
  9. Active and uncontrolled infections requiring intravenous antibiotic or antiviral treatment
  10. Patients with to IL-2 treatment according to the SmPC/package insert
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Dose level 2 ICT01 + Low dose SC IL-2

    For all arms, ICT01 IV is given on Day 1 of every 21-day cycle. SC IL-2 is administered Days 1-5 of cycles 1/2/3 only.

    Drug: ICT01 · Drug: Proleukin Injectable Product

  • Experimental
    Dose Level 1 ICT01 + High dose SC IL-2

    For all arms, ICT01 IV is given on Day 1 of every 21-day cycle. SC IL-2 is administered Days 1-5 of cycles 1/2/3 only.

    Drug: ICT01 · Drug: Proleukin Injectable Product

  • Experimental
    Dose level 1 ICT01 + Low dose SC IL-2

    For all arms, ICT01 IV is given on Day 1 of every 21-day cycle. SC IL-2 is administered Days 1-5 of cycles 1/2/3 only.

    Drug: ICT01 · Drug: Proleukin Injectable Product

  • Experimental
    Dose level 3 ICT01 + Low dose SC IL-2

    For all arms, ICT01 IV is given on Day 1 of every 21-day cycle. SC IL-2 is administered Days 1-5 of cycles 1/2/3 only.

    Drug: ICT01 · Drug: Proleukin Injectable Product

  • Experimental
    Dose level 4 ICT01 + Low dose SC IL-2

    For all arms, ICT01 IV is given on Day 1 of every 21-day cycle. SC IL-2 is administered Days 1-5 of cycles 1/2/3 only.

    Drug: ICT01 · Drug: Proleukin Injectable Product

  • Experimental
    Dose level 5 ICT01 + Low dose SC IL-2

    For all arms, ICT01 IV is given on Day 1 of every 21-day cycle. SC IL-2 is administered Days 1-5 of cycles 1/2/3 only.

    Drug: ICT01 · Drug: Proleukin Injectable Product

  • Experimental
    Primer Dose level 2 ICT01+ Low dose SC IL-2 + Booster Dose level 2 ICT01

    ICT01 IV is given on Day 1 of every 21-day cycle and on day 8 of Cycles 1-3. SC IL-2 is administered on Days 1-5 of Cycles 1/2/3 only.

    Drug: ICT01 · Drug: Proleukin Injectable Product

  • Experimental
    Primer Dose level 2 ICT01+ Low dose SC IL-2 + Booster Dose level 3 ICT01

    ICT01 IV is given on Day 1 of every 21-day cycle and on day 8 of Cycles 1-3. SC IL-2 is administered on Days 1-5 of Cycles 1/2/3 only.

    Drug: ICT01 · Drug: Proleukin Injectable Product

  • Experimental
    Dose level 2 ICT01 + Low dose SC IL-2 + Pembrolizumab

    ICT01 IV and Pembrolizumab are given on Day 1 of every 21-day cycle. SC IL-2 is administred Days 1-5 of cycles 1/2/3 only.

    Drug: ICT01 · Drug: Proleukin Injectable Product · Drug: Pembrolizumab injection

  • Experimental
    Dose level 4 ICT01 + Low dose SC IL-2 + Pembrolizumab

    ICT01 IV and Pembrolizumab are given on Day 1 of every 21-day cycle. SC IL-2 is administred Days 1-5 of cycles 1/2/3 only.

    Drug: ICT01 · Drug: Proleukin Injectable Product · Drug: Pembrolizumab injection

  • Experimental
    Primer Dose level 2 ICT01+ Low dose SC IL-2 + Pembrolizumab + Booster Dose level 2 ICT01

    ICT01 IV and Pembrolizumab are given on Day 1 of every 21-day cycle. ICT01 IV is given on day 8 of Cycles 1-3. SC IL-2 is administered on Days 1-5 of Cycles 1/2/3 only.

    Drug: ICT01 · Drug: Proleukin Injectable Product · Drug: Pembrolizumab injection

Interventions

06

What researchers measure

Primary outcomes

  1. Treatment-Emergent Adverse Events

    Incidence and severity of adverse events related to study treatment

    Time frame: 1 year

Secondary outcomes

  1. Change from baseline in the number of circulating g9d2 T cells

    flow cytometry measurement of circulating and intratumoral g9d2 T cells

    Time frame: Cycle Days 8 & 15 for the first 3 cycles

  2. Disease Control Rate

    Stable disease or better by RECIST1.1

    Time frame: 1 year

07

Study locations

5 sites
  • Institute Gustave Roussy
    Paris, France
  • IUCT Oncopole Claudius Regaud
    Toulouse, France
  • University Carl Gustav Carus
    Dresden, Germany
  • Universitätsklinikum Wuerzburg
    Würzburg, Germany
  • The Institute of Cancer Research
    Sutton, United Kingdom
08

References and documents

Publications

  • De Gassart A, Le KS, Brune P, Agaugue S, Sims J, Goubard A, Castellano R, Joalland N, Scotet E, Collette Y, Valentin E, Ghigo C, Pasero C, Colazet M, Guillen J, Cano CE, Marabelle A, De Bonno J, Hoet R, Truneh A, Olive D, Frohna P. Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vgamma9Vdelta2 T cell-mediated antitumor immune response. Sci Transl Med. 2021 Oct 20;13(616):eabj0835. doi: 10.1126/scitranslmed.abj0835. Epub 2021 Oct 20. PubMed 34669444 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2022 to primary completion in Oct 2025, 41 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2022
First posted
Apr 1, 2022
StartActual
May 4, 2022
Primary completionActual
Oct 9, 2025
CompletionActual
Oct 9, 2025
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05307874
Responsible party
Sponsor
First posted
Apr 1, 2022
Start date
May 4, 2022
Primary completion
Oct 9, 2025
Completion
Oct 9, 2025
Last update
Jul 30, 2026

Study contacts

Katrien Lemmens, MD, PhD
study director · ImCheck Therapeutics, an Ipsen company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anti-BTN3A Agonistic Monoclonal Antibody ICT01 · Aldesleukin

Start the discussion